Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CAPLIPOINT.NS
Strong BuyPremium GrowerCaplin Point Laboratories Limited · Healthcare · India · $2.2B · Avg Vol: $6M/d
86
StockRankGet insider-trade alerts
Q
80
V
25
M
78
P/E (TTM)
31.2x
ROE
17.9%
D/E
0.0x
Dividend %
0.3%
COMPANY DESCRIPTION
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.5B | 16.8B | 19.2B | 21.7B | 14.3% | 22.9B | 24.9B | 28.1B | 13.8% |
| EPS (INR) | 49.62 | 60.19 | 70.57 | 84.36 | 19.4% | 87.26 | 95.88 | 111.02 | 14.7% |
| Shares | 75.9M | 75.9M | 76.0M | 76.0M | +0.1% | 76.0M | — | — | — |
| Debt | 54.8M | 19.7M | 50.2M | 46.1M | -5.6% | 46.1M | — | — | — |
| Equity | 18.8B | 23.2B | 28.5B | 35.9B | 24.0% | — | — | — | — |
| Op CF | 2.7B | 3.2B | 4.3B | 5.2B | 24.5% | 5.2B | — | — | — |
| Inv CF | -2.2B | -3.2B | -3.3B | -5.8B | — | — | — | — | — |
| Fin CF | -281.7M | -380.7M | -383.2M | -464.6M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+4.2%
SMA 50SMA 200
Close
$28.63
RSI (14)
60.8
52W High
$30.25
From 52W High
0.9%
SCORE BREAKDOWN
Quality
80
ROIC
22.0%92.0
ROE
17.9%86.3
GP/Assets
33.9%69.5
Op. Margin
31.4%92.8
FCF/Assets
6.8%77.2
Piotroski
549.3
Int. Cover
50.0x89.2
D/E Ratio
0.00x93.4
Current Ratio
6.70x80.0
Value
25
P/E (TTM)
31.2x39.0
EV/EBITDA
25.4x26.0
P/FCF
76.8x19.9
P/B
5.9x23.4
P/S
9.0x27.7
Div Yield
0.3%6.9
Momentum
78
52W High %
95%93.1
RS 6M
67%93.6
SMA 50/200
1.26x91.3
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+27%39.5
Q Growth
16%51.7
FUNDAMENTALS
Market Cap
$2.2B
P/E (Forward)
24.6x
Gross Margin
60.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CAPLIPOINT.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CAPLIPOINT.NS | Caplin Point Laboratories Limited(you) | $2.2B | 86 | Strong Buy |
| GRANULES.NS | Granules India Limited | $2.3B | 87 | Strong Buy |
| APLLTD.NS | Alembic Pharmaceuticals Limited | $1.7B | 84 | Strong Buy |
| ALIVUS.NS | Alivus Life Sciences Limited | $1.8B | 91 | Strong Buy |
| VIYASH.NS | Viyash Scientific Limited | $1.2B | 88 | Strong Buy |
| EMCURE.NS | Emcure Pharmaceuticals Limited | $3.9B | 81 | Strong Buy |
| GLAND.NS | Gland Pharma Limited | $5.1B | 88 | Strong Buy |
| SHILPAMED.NS | Shilpa Medicare Limited | $2.0B | 69 | Buy |
| STAR.NS | Strides Pharma Science Limited | $1.2B | 93 | Strong Buy |
| NATCOPHARM.NS | NATCO Pharma Limited | $1.6B | 72 | Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%